Mirum Pharmaceuticals (MIRM) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Mirum Pharmaceuticals (MIRM) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 16.5% versus a loss of 26.2%. Over five years, MIRM leads with a +402.4% price change compared with -77.1% for RXRX. Mirum Pharmaceuticals is the larger company by market cap ($5.58 billion vs $2.34 billion), about 2.4 times the size.
Mirum Pharmaceuticals converts more of its revenue into profit, with a net margin of -4.5% versus -863.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIRM | RXRX |
|---|---|---|
| Share price | $86.01 | $4.36 |
| Market cap | $5.58B | $2.34B |
| 1-day change | +5.73% | +10.38% |
| YTD return | +8.89% | +6.60% |
| 1-year return | +16.51% | -26.23% |
| 5-year return | +402.39% | -77.10% |
| EPS (TTM) | $-14.10 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $521.31M | $74.68M |
| Revenue growth (YoY) | +54.74% | +26.92% |
| Net income (latest FY) | $-23.36M | $-644.76M |
| Gross margin | — | 4.99% |
| Operating margin | -4.25% | -867.87% |
| Net margin | -4.48% | -863.35% |
| 52-week high | $130.00 | $7.18 |
| 52-week low | $63.23 | $2.77 |
| Distance from 52-week high | -33.84% | -39.28% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +69.50% | +65.60% |
| Average volume | 695.76K | 20.70M |
| Shares outstanding | 64.93M | 535.34M |
| Employees | 433 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Mirum Pharmaceuticals is about 2.4 times larger than Recursion Pharmaceuticals by market value ($5.58B vs $2.34B).
- MIRM has outperformed RXRX by 42.7 percentage points over the past year.
- Mirum Pharmaceuticals is more profitable, keeping -4.5 cents of every revenue dollar as net income versus -863.4 cents for Recursion Pharmaceuticals.
- Mirum Pharmaceuticals grew revenue faster in its latest fiscal year (+54.74% vs +26.92%).
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
MIRM vs RXRX FAQ
Which is bigger, Mirum Pharmaceuticals or Recursion Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) is larger, with a market capitalization of $5.58B compared with $2.34B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, MIRM or RXRX?
MIRM returned +16.51% over the past 12 months, compared with -26.23% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Mirum Pharmaceuticals and Recursion Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Mirum Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Recursion Pharmaceuticals.